No headlines found.
No press releases found.
No news found.
Under normal circumstances, the Tema Cardiovascular and Metabolic ETF seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in publicly listed companies that derive at least 50% of revenues from products or services related to the treatment of cardiovascular diseases and/or metabolic diseases, as defined by the Centers for Diseases Control and Preventions. Companies include large pharmaceutical firms, development-stage biotechnology companies, diagnostic focused businesses with products used to diagnose and/or treat the aforementioned diseases, medical device companies focused on treatment of the aforementioned diseases, and healthcare service providers with a specific strategic focus on helping treat and manage the aforementioned diseases, each providing they meet the aforementioned revenue test.
Tema Cardiovascular And Metabolic ETF trades on the NASDAQ stock market under the symbol HRTS.
As of January 27, 2026, HRTS stock price declined to $36.14 with 2,102 million shares trading.
HRTS has a market cap of $57.46 million. This is considered a Micro Cap stock.
HRTS has outperformed the market in the last year with a price return of +21.8% while the SPY ETF gained +15.5%. HRTS has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +13.1% and +0.1%, respectively, while the SPY returned +2.9% and 0.0%, respectively.
HRTS support price is $36.02 and resistance is $36.74 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that HRTS shares will trade within this expected range on the day.
